Profusa (NASDAQ:PFSA – Get Free Report) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its rivals? We will compare Profusa to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Profitability
This table compares Profusa and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -880.32% |
| Profusa Competitors | -672.41% | -133.75% | -59.01% |
Earnings and Valuation
This table compares Profusa and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Profusa | N/A | -$8.71 million | -0.01 |
| Profusa Competitors | $59.54 million | -$32.15 million | 4.44 |
Analyst Ratings
This is a summary of recent ratings and price targets for Profusa and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| Profusa Competitors | 77 | 78 | 158 | 6 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 36.64%. Given Profusa’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
9.8% of Profusa shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 11.4% of Profusa shares are held by insiders. Comparatively, 18.4% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Profusa has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 1.76, meaning that their average stock price is 76% more volatile than the S&P 500.
Summary
Profusa rivals beat Profusa on 10 of the 13 factors compared.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
